USFDA inspection at Dr. Reddy's Srikakulam plant yields 5 Form 483 observations

Regulatory & Legal View source PDF Explain this filing

DRREDDY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.2%Reaction day

₹1280.00

prior close

₹1274.90

announcement price

After-mkt

timing

Nifty 100market · index membership as recorded later (tracked since Jun 2026)-0.0%-0.2% vs market

Pharmaceuticals peers, median of 155sector-0.1%-0.1% vs sector

On the reaction day the stock moved 0.2 pts less than Nifty 100 and 0.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.6

10m

-0.5

15m

-0.7

30m

-0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.2-0.0-0.2-0.1-0.1

Next day

-0.6-0.6+0.1-0.6+0.1

-0.6-0.8+0.2-1.3+0.7

+0.0-0.9+0.9-1.4+1.4

+0.0-0.3+0.3-0.6+0.6

+0.2+0.5-0.3-0.0+0.2

-1.0+0.4-1.4-0.0-1.0

15d

-2.0+0.9-2.9+0.7-2.7

-8.0-1.1-6.9-2.7-5.3

-0.9-0.9+0.0-4.9+3.9

-0.5-9.4+8.9-10.9+10.4

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

USFDA completed a GMP and Pre-Approval Inspection at Dr. Reddy's formulations facility (FTO-SEZ PU01) in Srikakulam, Andhra Pradesh, from December 4 to 12, 2025. The inspection ended with a Form 483 carrying 5 observations. The company says it will address the observations within the stipulated timeline.

Likely market impact

Minor near-term negative; Form 483 observations could push back product approvals from this plant. Routinely addressed by pharma companies.